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Background: Sorafenib is an oral multikinase inhibitor with antiangiogenic/antiproliferative activity. A randomized phase
2b screening trial in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer demonstrated a
significant improvement in progression-free survival (PFS) when sorafenib was added to capecitabine versus placebo
(median 6.4 versus 4.1 months; hazard ratio = 0.58; P = 0.001). Most drug-related adverse events were Grade 1/2 in
severity with the exception of Grade 3 hand-foot skin reaction/syndrome (44% versus 14%, respectively). These results
suggest a role for the combination of sorafenib and capecitabine in breast cancer and supported a phase 3 confirmatory
trial. Here we describe RESILIENCE - a multinational, double-blind, randomized, placebo-controlled, phase 3 trial - assessing
the addition of sorafenib to first- or second-line capecitabine in advanced HER2-negative breast cancer.
Methods/design: Eligibility criteria include ≥18 years of age, ≤1 prior chemotherapy regimen for metastatic
disease, and resistant to/failed taxane and anthracycline or no indication for further anthracycline. Prior treatment
with a vascular endothelial growth factor inhibitor is not allowed. Patients with significant cardiovascular disease
or active brain metastases are not eligible. Patients are stratified by hormone-receptor status, geographic region,
and prior metastatic chemotherapy status and randomized (1:1) to capecitabine (1000 mg/m2 orally twice daily
(BID), days 1 to 14 of 21) in combination with sorafenib (orally BID, days 1 to 21, total dose 600 mg/day) or
matching placebo. Capecitabine and sorafenib/placebo doses can be escalated to 1250 mg/m2 BID and 400 mg
BID, respectively, as tolerated, or reduced to manage toxicity. Dose re-escalation after a reduction is allowed for
sorafenib/placebo but not for capecitabine. This dosing algorithm was designed to mitigate dermatologic and
other toxicity, in addition to detailed guidelines for prophylactic and symptomatic treatment. Radiographic
assessment is every 6 weeks for 36 weeks, and every 9 weeks thereafter. The primary endpoint is PFS by blinded
independent central review (Response Evaluation Criteria in Solid Tumors 1.1 criteria). Secondary endpoints
include overall survival, time to progression, overall response rate, duration of response, and safety. Enrollment
began in November 2010 with a target of approximately 519 patients.
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Discussion: RESILIENCE will provide definitive PFS data for the combination of sorafenib and capecitabine in
advanced HER2-negative breast cancer and better characterize the benefit-to-risk profile.
Trial registration: Clinicaltrials.gov, NCT01234337
Keywords: Metastatic breast cancer, Sorafenib, CapecitabineBackground
In recent decades, advances in the treatment of metastatic
breast cancer (MBC) have provided incremental improve-
ment in disease control and survival [1]. Novel chemo-
therapies (for example, paclitaxel, capecitabine) for MBC
and the introduction of hormone and other targeted ther-
apies (for example, trastuzumab) have corresponded to a
steady increase in survival. Despite these improvements,
the primary goal of treatment remains palliative with
about half of patients succumbing to the disease within 3
years [1-4].
Breast cancer is a heterogenous disease with systemic
treatment options primarily based on hormone receptor
and human epidermal growth factor receptor 2 (HER2)
status, but also emerging therapies that target other mo-
lecular pathways involved in development, progression,
resistance, and metastasis, such as antiangiogenics and
poly(adenosine diphosphate ribose) polymerase (PARP)
inhibitors [5]. While management of early disease stages is
well defined, management of MBC, particularly HER2-
negative disease, is complex as standard treatment strat-
egies are not well established [6,7]. The optimal sequence
or combination of agents has not been standardized and is
dependent on a variety on intra-patient factors. Combin-
ation chemotherapy regimens have been shown to provide
clinical benefit in MBC but are associated with significant
toxicities and have not shown an overall survival (OS)
benefit compared with sequential use of agents [3,8,9].
Novel combinations are needed that improve survival,
disease control, and quality of life (QoL) with acceptable
toxicity.
Although single-agent use of antiangiogenics has
demonstrated only modest efficacy in MBC [10-14],
studies in HER2-negative MBC have demonstrated the
clinical benefit of adding antiangiogenics to chemo-
therapy. This was first established with bevacizumab, a
monoclonal antibody targeting vascular endothelial
growth factor (VEGF), a potent angiogenic factor [15-19].
In the E2100 phase 3 study, the addition of bevacizumab
to first-line paclitaxel demonstrated a clinically significant
improvement in progression-free survival (PFS) for pa-
tients with HER2-negative MBC [16]. PFS increased from
5.9 months for paclitaxel alone to 11.8 months for
bevacizumab plus paclitaxel (hazard ratio [HR] = 0.60;
95% confidence interval [CI] = 0.51 to 0.70; P < 0.001).The combination was tolerable, although some serious
events occurred infrequently. Subsequent studies of
bevacizumab in combination with selected chemother-
apies have also demonstrated significant improvement in
PFS, but the benefit has been notably more modest than
the E2100 results [15,18,19]. Furthermore, an OS benefit
has not been demonstrated across these bevacizumab
studies.
A number of factors might explain the discrepancy be-
tween the PFS benefit and the lack of improvement in
OS. It is difficult to demonstrate an OS benefit in first-
line MBC because treatments after progression likely
confound data [20]. In addition, preclinical data suggest
that antiangiogenic treatment may result in more aggres-
sive disease at the time of progression, possibly through
increased invasiveness of tumor cells and/or by switching
to alternative angiogenic pathways to re-establish tumor
vascularization [21,22]. This led clinicians to investi-
gate whether other antiangiogenic agents that have a
broader spectrum of activity than bevacizumab, such
as the tyrosine kinase inhibitors sunitinib and sorafenib,
might provide benefit in HER2-negative MBC. While
phase 3 studies with sunitinib have been disappoint-
ing thus far [10,23-25], a series of phase 2b randomized,
placebo-controlled trials have collectively demonstrated
sorafenib activity when combined with selected chemo-
therapies [26-29].
Sorafenib, an oral multikinase inhibitor with both
antiproliferative and antiangiogenic activity, is indicated
for advanced renal cell and hepatocellular carcinomas
[30,31]. Sorafenib targets VEGF receptors-1, -2, and −3,
platelet-derived growth factor receptor β, Raf kinase, c-KIT,
and Flt-3 [32]. Preclinical data in breast tumor models sug-
gest that adding sorafenib to cytotoxic agents may provide
synergistic/additive antitumor effects and may help over-
come resistance to cytotoxic agents [33-35].
The Trials to Investigate the Efficacy of Sorafenib (TIES)
in Breast Cancer Program was developed to rapidly assess
the efficacy and safety of sorafenib in combination with
selected systemic therapies for HER2-negative MBC, to
determine if phase 3 confirmatory trials should be
pursued, and to inform the design of these trials. The TIES
program was developed by independent investigators with
support from industry to collectively identify settings in
HER2-negative MBC where the addition of sorafenib
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blind, randomized, placebo-controlled, phase 2b screening
trials in patients with HER2-negative advanced breast
cancer that assessed sorafenib in combination with first-
or second-line capecitabine (SOLTI-0701) [26], first-line
paclitaxel (NU07B1) [28], first- or second-line gemcitabine
or capecitabine (AC01B07) in patients who had progressed
during or after a regimen containing bevacizumab [27],
and first-line docetaxel and/or letrozole (FM-B07-01) [29].
Two of the TIES programs indicated a potential role for
sorafenib in this patient population when used in combin-
ation with selected chemotherapies [26,27]. More specif-
ically, results of the SOLTI-0701 supported a phase 3
confirmatory study of the sorafenib-capecitabine com-
bination [26]. AC01B07 also met its primary endpoint,
but the PFS benefit with the sorafenib combination was
too modest to support a phase 3 trial of similar design
[27]. NU07B1 did not demonstrate a statistically signifi-
cant benefit in PFS with the sorafenib combination but
showed a statistically significant improvement in time to
progression (TTP) [28]. There was no clinical benefit asso-
ciated with the sorafenib combination in the FM-B07-01
study [29].
During SOLTI-0701, the addition of sorafenib to first-
or second-line capecitabine significantly improved the
primary endpoint of PFS compared with placebo (median
6.4 versus 4.1 months; HR = 0.58; 95% CI = 0.41 to 0.81;
P = 0.001) and the secondary endpoint of TTP (median
6.8 versus 4.1 months; HR = 0.56; 95% CI = 0.39 to 0.80;
P = 0.001) [26]. There was no significant improvement
in overall survival (median 22.2 versus 20.9 months;
HR = 0.86; 95% CI = 0.61 to 1.23; P = 0.42).
Generally, the combination of sorafenib and capecitabine
was manageable, but dose reductions were more com-
mon than in the placebo arm [26]. During SOLTI-0701,
the starting dose was 1000 mg/m2 twice daily (BID)
capecitabine (first 14 days of a 21-day cycle) and 400 mg
BID (continuously) for sorafenib/placebo. Dose interrup-
tions and reductions were allowed to manage toxicity.
Dose reductions in the sorafenib arm were 53% for
sorafenib and 78% for capecitabine compared with 14%
for placebo and 33% for capecitabine in the placebo arm.
The average daily dose of study drugs was lower in the
sorafenib arm (mean 584 mg sorafenib and 1461 mg/m2
capecitabine) compared with the placebo arm (mean 745
mg placebo and 1839 mg/m2 capecitabine). Most patients
remained on treatment until disease progression in the
sorafenib and placebo arms (63% and 82%), but some
discontinued treatment due to adverse events (AEs) (20%
versus 9%, respectively). The average duration of treat-
ment in the sorafenib arm was 33.8 weeks for sorafenib
and 33.1 weeks for capecitabine, with corresponding
values of 22.5 and 22.2 weeks in the placebo arm. The
most common toxicity was hand-foot skin reaction(HFSR) associated with sorafenib and hand-foot syndrome
(HFS) associated with capecitabine, which occurred more
frequently in the sorafenib arm than the placebo arm (90%
versus 66% for any grade and 44% versus 14% for Grade 3)
and occurred earlier (median time to onset 14 versus 64
days, respectively, for any grade). Other Grade 3/4 events
were comparable between the groups.
The results of SOLTI-0701 supported the rationale for
a similar confirmatory trial in the phase 3 setting, but
also indicated that the study design would require
amendments to the dosing schema to address the inci-
dence of HFSR/HFS in addition to more aggressive pre-
vention and management strategies. Here we present
the study design of the phase 3 RESILIENCE trial (tRial
comparing capecitabinE in combination with SorafenIb
or pLacebo for treatment of locally advanced or meta-
statIc HER2-Negative breast CancEr).
Methods/design
RESILIENCE is a multinational, randomized, double-
blind, placebo-controlled, phase 3 trial designed to as-
sess the efficacy and safety of sorafenib in combination
with capecitabine in patients with locally advanced or
metastatic HER2-negative breast cancer who received
previous treatment with a taxane and anthracycline.
The study is being conducted in accordance with Good
Clinical Practice guidelines, the guiding principles of
the Declaration of Helsinki, and applicable local laws
and regulations. The study protocol has been approved
by both Regulatory Authorities and internal review
boards of the participating centers. All patients will
provide written informed consent. The trial is registered
at ClinicalTrials.gov (NCT01234337). (For a complete
listing of study centers see Additional file 1).
Patient population and study design
Patients at least 18 years of age with HER2-negative ad-
vanced breast cancer who have been treated with a max-
imum of one prior chemotherapy regimen for metastatic
disease are eligible to enroll. Prior treatment with both a
taxane and an anthracycline is required, but prior treat-
ment with a VEGF inhibitor (for example, bevacizumab)
is not allowed. Table 1 summarizes major eligibility
criteria. Patients will be stratified by hormone-receptor
status (estrogen and/or progesterone receptor positive
versus both negative), geographic region (North America
versus Europe versus Other), and number of prior MBC
chemotherapy regimens (0 or 1), then randomized (1:1)
to receive either sorafenib or placebo in combination
with capecitabine (Figure 1).
Patients will receive sorafenib or matching placebo
BID on a continuous basis. The initial daily dose of
sorafenib is 600 mg taken as one 200-mg tablet in
the morning and two 200-mg tablets in the evening.
Table 1 Eligibility criteria for RESILIENCE
Key inclusion criteria Key exclusion criteria
● Age ≥18 years ● HER2-positive disease
● Life expectancy ≥12 weeks ● Unknown estrogen and progesterone receptor status
● Histologically or cytologically confirmed HER2-negative breast adenocarcinoma ● Previous treatment with a VEGF inhibitor
● Locally advanced (non-resectable) or metastatic disease ● Symptomatic brain metastases
● Measurable or clinically evaluable disease according to Response Evaluation Criteria
in Solid Tumors (RECIST 1.1)
● Recent (<4 weeks before entry) major surgery, open
biopsy, or significant traumatic injury
● Resistant to or failed prior taxane and an anthracycline or further anthracycline
therapy is not indicated
● Uncontrolled hypertension, or active or clinically
significant cardiac disease
● No more than one previous chemotherapy regimen for metastatic disease ● Thrombotic, embolic, venous, or arterial events, or other
bleeding disorders within the past 6 months
● Prior adjuvant or neoadjuvant chemotherapy allowed ● Any hemorrhage/bleeding event of Grade 3 or above
within past 4 weeks
● Prior hormonal therapy for locally advanced or metastatic disease allowed
● Prior chemotherapy, radiation, or hormonal therapy discontinued ≥4 weeks before
randomization; previously irradiated areas must not be the only site of disease
● ECOG Performance Status of 0 or 1
● Adequate hepatic and renal function
ECOG Eastern Cooperative Oncology Group, HER2 human epidermal growth factor receptor 2, RESILIENCE tRial comparing capecitabinE in combination with
SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr, VEGF vascular endothelial growth factor.
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the average daily dose (mean 584 mg/day) in the sorafenib
arm of the SOLTI-0701 study [26]. Capecitabine is admin-
istered orally on days 1 through 14 of a 21-day cycle at a
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erated (fatigue, dermatologic toxicities, or gastrointestinal
toxicities are no greater than Grade 1) after a 21-day cycle. mg/day po
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aring capecitabinE in combination with SorafenIb or pLacebo for
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Table 2 Recommended prevention/management
strategies for skin toxicities consistent with hand-foot
skin reaction/hand-foot syndrome




● Maintain frequent contact with trial physician
to ensure early diagnosis of HFSR
● Practical prevention strategies
○ Pedicure by a podiatrist for subjects with
pre-existing hyperkeratosis
○ Subjects should avoid hot water, and
clothing or activities that can cause friction on
the skin
○ Moisturizing cream should be applied
sparingly
● Padded gloves and open shoes with padded
soles should be worn to relieve pressure points
Grade 1 any
occurrence
● Continue preventive strategies and in addition:
○ Soak hands in cool water
○ Apply petroleum jelly to moist skin
● In the case of hyperkeratotic lesions, exfoliate
the hands or feet and apply moisturizing cream
immediately afterwards
Grade 2 or 3 any
occurrence
● Continue supportive/management measures
and add analgesic(s) for pain
● Dose modifications to study treatments per
protocol guidance
HFS: hand-foot syndrome, HFSR: hand-foot skin reaction.
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ated in a 21-day cycle, then the capecitabine dose may be
increased to 1250 mg/m2 BID in the subsequent cycle.
Management of adverse events
Dose reductions, interruptions, and discontinuation of
study drugs are required to manage toxicity and are de-
tailed in the study protocol by toxicity type and grade,
which also specifies how dosing of the study drug(s)
should be modified. Re-escalation of sorafenib/placebo
after a dose reduction is permitted per protocol guidance,
but dose re-escalation is not permitted for capecitabine as
per the capecitabine label. If an AE leads to dose interrup-
tion of more than 21 days, recurs too frequently and leads
to dose reductions, and/or is too severe (for example,
Grade 4 non-hematologic toxicities), one or both study
drugs may be permanently discontinued. Sorafenib treat-
ment cannot be continued if capecitabine has been
discontinued permanently, but capecitabine may continue
if sorafenib has been permanently discontinued. Proactive
management of HFSR/HFS leads to better management of
these toxicities, allowing patients to remain on treatment.
Based on the experience in the SOLTI-0701 study, the
RESILIENCE protocol includes comprehensive guidelines
for prophylactic management (for example, pedicure and
moisturizing creams) and symptomatic treatment (for
example, topical exfoliants and analgesics) of HFSR/HFS
(Table 2), in addition to dose modifications of study drugs.
Assessments
Electrocardiogram, blood tests, patient QoL question-
naires, a complete physical examination, and assess-
ment of Eastern Cooperative Oncology Group (ECOG)
performance status will be performed at the beginning
of each treatment cycle. On a weekly basis during the
first 6 weeks of treatment, patients will undergo a brief
physical examination comprising assessment of vital
signs and a thorough dermatologic examination for
HFSR/HFS and other dermatologic toxicities.
Tumor measurements during the study will be conducted
using computed tomography scan and/or magnetic reson-
ance imaging, with a bone scan if clinically indicated at the
time of screening, on day 1 of Cycle 1 and every 6 weeks
from the day of randomization through week 36, and then
every 9 weeks thereafter. Treatment response will be evalu-
ated using Response Evaluation Criteria in Solid Tumors
(RECIST 1.1) criteria [37].
Study endpoints
Primary and secondary endpoints
The primary efficacy endpoint is PFS by blinded inde-
pendent central review. Secondary efficacy endpoints are
OS, TTP, overall response rate (ORR), and duration of re-
sponse (DoR). Safety evaluations comprise AE reportingby standard methods (National Cancer Institute-Common
Terminology Criteria for Adverse Events v4.0) and assess-
ment of laboratory abnormalities.
Patient-reported outcomes
Patient-reported outcomes (PROs) include an evaluation
of breast cancer symptoms using the Functional Assess-
ment of Cancer Therapy-Breast Symptom Index (8 items)
(FBSI-8 questionnaire) [38,39] and health-related quality
of life (HRQoL) using the EuroQoL 5-Dimension Ques-
tionnaire (EQ-5D) [40].
Pharmacokinetics
Pharmacokinetic analysis of capecitabine, 5-fluorouracil
(5-FU) (the active metabolite of capecitabine), and
sorafenib exposures will be conducted. Five blood sam-
ples each will be collected from approximately 200 pa-
tients for these analyses. On day 14 of Cycle 2, samples
will be obtained prior to and at 0.5, 1, 2, and 4 hours after
the capecitabine dose to estimate capecitabine and 5-FU
exposure. Sorafenib exposure will be estimated from a
single blood sample on day 14 of Cycle 2.
Exploratory biomarkers
Exploratory analyses of cancer biomarkers such as
PIK3CA, BRAF, and KRAS will be performed to possibly
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sponse to sorafenib treatment. Plasma samples for bio-
marker analysis (genetic and non-genetic) will be collected
at screening, prior to drug administration in Cycles 1
through 3, and at the end of treatment. Permission to
obtain an archived biopsy sample from diagnosis or later
will be sought from all patients during screening.
Statistical analyses
Assuming a 1-sided alpha of 0.005, a power of 98.9%,
and a randomization ratio of 1:1 between the sorafenib
and placebo groups, 363 events are required to detect a
66.7% increase in PFS. Assuming enrollment at a rate of
20 patients per month, an enrollment ramp-up time of 4
months, a dropout rate of 10%, an exponentially distrib-
uted event time, 4.5-month median PFS for the control
group, and a 28.4-month enrollment period, a sample
size of 519 is estimated with an expected trial duration
of 31.4 months.
Efficacy analyses will be performed with the intent-to-
treat population. The primary analysis of the study will
be performed after approximately 363 PFS events. Ana-
lysis of PFS will be performed using a log-rank test,
stratified by randomization factors (that is, hormone-
receptor status, geographic region, and prior chemo-
therapy for MBC) with 1-sided alpha of 0.005. All
secondary time-to-event endpoints (OS, TTP and
DoR) will be analyzed in a similar manner but with
a 2-sided alpha of 0.05.
Assuming a median OS of 12 months for the control
group, approximately 270 deaths would be expected at the
time of the primary analysis of PFS, at which time an
interim analysis of OS is planned. For the final analysis of
OS, 405 deaths are projected to occur by approximately
47.9 months after the first patient is randomized. Analysis
of 405 events will provide 82% power to detect a 33.3%
increase in survival with sorafenib compared with placebo
with a 2-sided alpha of 0.05, assuming one interim analysis
of OS at the time of the PFS analysis. The interim and
final analyses of OS will be performed using an O’Brien-
Fleming type alpha spending function.
For other endpoints, a Cochran-Mantel-Haenszel test
with the randomization factors as strata will be used to
compare ORR between treatment arms. PROs will be
analyzed by time-adjusted area under the curve with the
comparison between treatment arms made using a
covariance analysis, if appropriate. The predictive value
of baseline biomarker levels (genetic and non-genetic)
for the treatment effect in PFS and OS will be assessed
using appropriate statistics to determine whether any of
the known biological targets of sorafenib are important
in assessing efficacy. In addition, correlations between
change in biomarker levels from baseline and PFS and
OS will be investigated.Discussion
Data from the SOLTI-0701 showed a statistically signifi-
cant improvement in PFS when sorafenib was added to
capecitabine as a first- or second-line treatment and
supported and informed the development of the phase 3
RESILIENCE study [26]. The RESILIENCE study is simi-
lar in design to SOLTI-0701 but with some differences
in total daily dose of sorafenib. RESILIENCE will provide
definitive PFS data for the addition of sorafenib to
capecitabine in patients with advanced breast cancer. It
will better characterize the benefit-to-risk profile for
these doses of sorafenib and capecitabine and provide
information on the benefits of prophylactic management
and treatment of HFSR/HFS. Because of the high inci-
dence of HFSR/HFS during SOLTI-0701 as well as the
sorafenib mean dose of 584 mg, the RESILIENCE study
will start sorafenib at a 600 mg/day (200 mg in the
morning and 400 mg in the evening) dose with ability to
titrate the dose up to 400 mg BID as tolerated or down
to manage toxicity. For SOLTI-0701, the dosing schema
started at the highest sorafenib dose of 400 mg BID with
the option of titrating down only to manage toxicity. It
is of clinical interest to determine if the modifications to
the dosing schema from SOLTI-0701 to RESILIENCE, in
addition to more aggressive prophylactic and symptomatic
treatment guidance, mitigate the incidence, duration, and
severity of HFSR/HFS as well as influence the duration of
treatment for the sorafenib arm.
The RESILIENCE study will also provide more ro-
bust OS data. The SOLTI-0701 study failed to show a
difference between treatment arms for OS, but these
were phase 2b studies that were not powered for such
an analysis [26]. Of interest, a trend of improved sur-
vival was observed in the first-line treatment subgroup
of the SOLTI-0701 study (HR = 0.67; 95% CI = 0.40 to
1.11) but not in the second-line treatment subgroup
(HR = 1.08; 95% CI = 0.65 to 1.78).
The PROs of RESILIENCE will help to better define
the benefit-to-risk profile of the sorafenib-capecitabine
combination. Maintaining patient QoL has become an
important clinical goal of MBC treatment. Although
toxicities associated with sorafenib, like HFSR/HFS, are
reversible and non-life threatening in most cases, they
can have a significant impact on QoL [41]. In addition,
the exploratory analysis of biomarkers may help to bet-
ter characterize the effect of disease biology on treat-
ment response that may be useful in the design of future
studies, particularly those that investigate the impact of
patient selection on clinical outcomes.
The RESILIENCE study is an essential step for the
development of sorafenib in MBC, as it will provide
definitive PFS data and more definitive OS data and
inform on the management of HFSR/HFS. An effective
all-oral combination regimen for HER2-negative disease
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mentarium in this patient population [42].Trial status
The RESILIENCE study began enrolling patients in
November 2010. The study is being conducted in more
than 20 countries and 200 investigational sites.Additional file
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